• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    5/2/24 8:06:54 AM ET
    $AKAN
    $ALLR
    $APVO
    $ARAY
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • Allarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million.
    • Emergent BioSolutions (NYSE:EBS) shares moved upwards by 52.84% to $2.95. The market value of their outstanding shares is at $154.5 million. As per the press release, Q1 earnings came out yesterday.
    • Aptevo Therapeutics (NASDAQ:APVO) stock rose 35.41% to $1.3. The company's market cap stands at $4.6 million.
    • Context Therapeutics (NASDAQ:CNTX) stock rose 34.55% to $1.83. The company's market cap stands at $29.2 million.
    • Skye Bioscience (NASDAQ:SKYE) stock increased by 25.09% to $16.0. The company's market cap stands at $449.0 million.
    • Butterfly Network (NYSE:BFLY) stock increased by 24.52% to $0.98. The market value of their outstanding shares is at $203.9 million. The company's, Q1 earnings came out yesterday.

    Losers

    • Akanda (NASDAQ:AKAN) stock fell 12.5% to $0.1 during Thursday's pre-market session. The market value of their outstanding shares is at $1.2 million.
    • CytomX Therapeutics (NASDAQ:CTMX) stock fell 11.7% to $4.53. The company's market cap stands at $306.8 million.
    • Accuray (NASDAQ:ARAY) stock decreased by 11.06% to $1.93. The market value of their outstanding shares is at $191.4 million. As per the press release, Q3 earnings came out yesterday.
    • Concord Medical Services (NYSE:CCM) shares decreased by 10.92% to $0.68. The market value of their outstanding shares is at $29.5 million.
    • DBV Technologies (NASDAQ:DBVT) stock declined by 9.95% to $0.62. The company's market cap stands at $119.8 million.
    • Pharming (NASDAQ:PHAR) shares decreased by 9.86% to $9.42. The company's market cap stands at $634.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $ALLR
    $APVO
    $ARAY

    CompanyDatePrice TargetRatingAnalyst
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    DBV Technologies S.A.
    $DBVT
    12/15/2025$42.00Overweight
    Cantor Fitzgerald
    DBV Technologies S.A.
    $DBVT
    12/3/2025$35.00Buy
    Guggenheim
    CytomX Therapeutics Inc.
    $CTMX
    9/22/2025$6.00Overweight
    Cantor Fitzgerald
    Context Therapeutics Inc.
    $CNTX
    9/18/2025$5.00Buy
    Guggenheim
    CytomX Therapeutics Inc.
    $CTMX
    9/17/2025$3.50Overweight
    Barclays
    Butterfly Network Inc.
    $BFLY
    8/1/2025Outperform → Perform
    Oppenheimer
    CytomX Therapeutics Inc.
    $CTMX
    7/31/2025$7.00Outperform
    Oppenheimer
    More analyst ratings

    $AKAN
    $ALLR
    $APVO
    $ARAY
    SEC Filings

    View All

    Butterfly Network Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Butterfly Network, Inc. (0001804176) (Filer)

    2/26/26 7:00:48 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    2/19/26 8:00:48 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

    SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    2/17/26 6:23:44 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ALLR
    $APVO
    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on CytomX Therapeutics with a new price target

    Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00

    1/20/26 9:23:09 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on DBV Technologies with a new price target

    Cantor Fitzgerald initiated coverage of DBV Technologies with a rating of Overweight and set a new price target of $42.00

    12/15/25 9:59:53 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on DBV Technologies with a new price target

    Guggenheim initiated coverage of DBV Technologies with a rating of Buy and set a new price target of $35.00

    12/3/25 8:16:35 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKAN
    $ALLR
    $APVO
    $ARAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Legal Officer, Corp. Sec Levit Alex C.

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    2/23/26 4:24:53 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Minai-Azary Jennifer Lynn

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    2/23/26 4:21:41 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Chagin Karen Deborah

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    2/23/26 4:18:52 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ALLR
    $APVO
    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Butterfly Network Reports Fourth Quarter 2025 Financial Results

    Delivered Record Annual and Quarterly Revenue Reported quarterly record Revenue of $31.5 million in Q4, representing 41% YoY growth Generated positive net cash flow of $6.3 million in Q4 and lowest annual cash usage in company history Midjourney partnership contributed $6.8 million of revenue in Q4, advancing Butterfly Embedded™ platform strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's Presiden

    2/26/26 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12

    Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year 2025 and provide a business update on Thursday, March 12, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/08:30 am EDT. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration:https://register-conf.media-server.com/register/BIb3649a77439d4a2d8e5e002bac980cd1 Once registered, dial-in information and a unique PIN will

    2/26/26 2:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

         Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for enrollment at 11 VA sites nationwide Relapsed SCLC remains an area of high unmet need without effective treatment options TARPON SPRINGS, Fla., February 18, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the first patients have been dosed with stenoparib and temozolomide in the VA-funded investi

    2/18/26 8:15:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ALLR
    $APVO
    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mayer Steven F bought $30,878 worth of shares (54,875 units at $0.56), increasing direct ownership by 4% to 1,545,620 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/23/26 4:10:08 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Director Mayer Steven F bought $103,797 worth of shares (195,125 units at $0.53), increasing direct ownership by 15% to 1,490,745 units (SEC Form 4)

    4 - ACCURAY INC (0001138723) (Issuer)

    2/20/26 4:10:06 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    $ALLR
    $APVO
    $ARAY
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

    GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) announced today that Dr. Louis W. Sullivan will retire from the company's Board of Directors effective November 14 after 19 years of service to the company and its shareholders. "For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent's mission to protect and save lives," said Joe Papa, president and CEO of Emergent. "On behalf of the Board and the entire Emergent team, I want to thank him for his distinguished leadership and contributions. We wish him all the best." Dr. Sullivan served on Emergent's Board of Directors since 2006, and most recently served as chair of the

    11/12/25 4:01:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

    Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin® Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA su

    11/3/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKAN
    $ALLR
    $APVO
    $ARAY
    Financials

    Live finance-specific insights

    View All

    Butterfly Network Reports Fourth Quarter 2025 Financial Results

    Delivered Record Annual and Quarterly Revenue Reported quarterly record Revenue of $31.5 million in Q4, representing 41% YoY growth Generated positive net cash flow of $6.3 million in Q4 and lowest annual cash usage in company history Midjourney partnership contributed $6.8 million of revenue in Q4, advancing Butterfly Embedded™ platform strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's Presiden

    2/26/26 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12

    Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year 2025 and provide a business update on Thursday, March 12, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/08:30 am EDT. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration:https://register-conf.media-server.com/register/BIb3649a77439d4a2d8e5e002bac980cd1 Once registered, dial-in information and a unique PIN will

    2/26/26 2:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of

    2/12/26 9:02:20 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ALLR
    $APVO
    $ARAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Context Therapeutics Inc.

    SC 13G/A - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:31:29 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Context Therapeutics Inc.

    SC 13G - Context Therapeutics Inc. (0001842952) (Subject)

    11/14/24 5:05:15 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    11/14/24 4:55:56 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care